PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2016.168PMID 27805626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.

  2017cited by this paper
• Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

  2016cited by this paper
• Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

  2016cited by this paper
• PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

  2016cited by this paper
• Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

  2016cited by this paper
• Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

  2016cited by this paper
• Immunotherapy: Study deciphers enigmatic mechanism of PD-L1 overexpression

  2016cited by this paper
• Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

  2016cited by this paper
• Follicular lymphoma: evolving therapeutic strategies.

  2016cited by this paper
• Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

  2016cited by this paper
• Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

  2016cited by this paper
• A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity

  2016cited by this paper
• Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

  2016cited by this paper
• Genetic and Epigenetic Regulation of PD-1 Expression

  2016cited by this paper
• PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

  2016cited by this paper
• PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.

  2016cited by this paper
• Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

  2016cited by this paper
• Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.

  2016cited by this paper
• Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

  2016cited by this paper
• Human immunodeficiency virus‐associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base

  2016cited by this paper
• Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma

  2016cited by this paper
• Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.

  2016cited by this paper
• Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

  2016cited by this paper
• New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT

  2016cited by this paper
• Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

  2016cited by this paper
• Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

  2015cited by this paper
• Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• How I treat advanced classical Hodgkin lymphoma.

  2015cited by this paper
• Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options

  2015cited by this paper
• Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

  2015cited by this paper
• Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling

  2015cited by this paper
• Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

  2015cited by this paper
• B7H1/CD80 Interaction Augments PD-1–Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease

  2015cited by this paper
• Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation

  2015cited by this paper
• Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice

  2015cited by this paper
• Analysis of the National Cancer Data Base to Describe Treatment Trends in Stage IV Oral Cavity and Pharyngeal Cancers in the United States, 1998-2012.

  2015cited by this paper
• Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.

  2015cited by this paper
• Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

  2015cited by this paper
• Structural genomic alterations in primary mediastinal large B-cell lymphoma

  2015cited by this paper
• Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

  2015cited by this paper
• PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

  2015cited by this paper
• Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

  2015cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma

  2014cited by this paper
• History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.

  2014cited by this paper
• Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

  2014cited by this paper
• Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

  2014cited by this paper
• Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma

  2014cited by this paper
• Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

  2014cited by this paper
• Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain

  2014cited by this paper
• Diagnosis and management of lymphomas and other cancers in HIV-infected patients

  2014cited by this paper
• Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.

  2014cited by this paper
• High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

  2014cited by this paper
• Targetable genetic features of primary testicular and primary central nervous system lymphomas.

  2014cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

  2013cited by this paper
• Identification of T follicular helper (Tfh) cells by flow cytometry

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

  2013cited by this paper
• Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas

  2013cited by this paper
• Update on the treatment of HIV-associated hematologic malignancies.

  2013cited by this paper
• High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

  2013cited by this paper
• The role of B7 family molecules in hematologic malignancy.

  2013cited by this paper
• Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

  2013cited by this paper
• Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells

  2013cited by this paper
• Inadequate T follicular cell help impairs B cell immunity during HIV infection

  2013cited by this paper
• PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

  2013cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

  2013cited by this paper
• Love the one you're with: the HIV, B cell and TFH cell triangle

  2013cited by this paper
• Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

  2013cited by this paper
• Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

  2012cited by this paper
• Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.

  2012cited by this paper
• Lenalidomide enhances anti-myeloma cellular immunity

  2012cited by this paper
• How I treat HIV-associated lymphoma.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

  2012cited by this paper
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012cited by this paper
• Review of the cardiac long‐term effects of therapy for Hodgkin lymphoma

  2011cited by this paper
• Follicular helper CD4 T cells (TFH).

  2011cited by this paper

• Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies

  2026cites this paper
• Oridonin downregulates PD-L1 expression and promotes anti-tumor immunity via inhibiting NLRP3 and STAT3.

  2026cites this paper
• Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review

  2026cites this paper
• PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.

  2026cites this paper
• Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology.

  2026cites this paper
• Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response

  2026cites this paper
• The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.

  2026cites this paper
• IgG4-Positive Ocular Adnexal Extranodal Marginal Zone Lymphoma as an Aggressive Clinical Subtype: Evidence from a 377-Patient Cohort.

  2026cites this paper
• Integrated computational pipeline for advanced sampling-based investigation and alternative inhibition of the programmed cell death protein I pathway

  2025cites this paper
• Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma

  2025cites this paper
• Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience

  2025cites this paper
• The PD-1/PD-L1 pathway and Epstein–Barr virus

  2025cites this paper
• Evaluation of CD73, PD-1, circHIPK3, and circNRIP1 expression in the peripheral blood of patients with colorectal cancer.

  2025cites this paper
• Immune Checkpoint Molecule Expression, 9p24.1 Gene Alterations, and Tumor Microenvironment of Primary Central Nervous System Lymphomas and Their Clinical Relevance.

  2025cites this paper
• Simultaneous Induction of Immunogenic Pyroptosis and PD-L1 Downregulation by One Single Photosensitizer for Synergistic Cancer Photoimmunotherapy.

  2025cites this paper
• Remodeling of Effector and Regulatory T Cells by Capture and Utilization of miRNAs Using Nanocomposite Hydrogel for Tumor-Specific Photothermal Immunotherapy.

  2025cites this paper
• Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update

  2025cites this paper
• Copper metabolism and cuproptosis: broad perspectives in the treatment of hepatocellular carcinoma

  2025cites this paper
• The Tumor Microenvironment Remodeled by Epstein-Barr Virus: From Primary Site to Distant Metastatic Niche.

  2025cites this paper
• Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities

  2025cites this paper
• Organic Semiconducting Polymers for Cancer Sonodynamic Immunotherapy

  2025cites this paper
• Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy

  2025cites this paper
• Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis.

  2025cites this paper
• 免疫检查点抑制剂在前列腺癌治疗中的临床应用进展

  2025cites this paper
• HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?

  2025cites this paper
• Self-Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD-L1 Upregulation.

  2025cites this paper
• Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment

  2025cites this paper
• Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies

  2025cites this paper
• The expression and prognosis for Aurora kinases in human non-small cell lung cancer

  2025cites this paper
• Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis

  2025cites this paper
• Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management

  2025cites this paper
• Super-Resolution Microscopy Reveals Nanoscale Arrangement of PD-L1 Immune Checkpoint

  2025cites this paper
• Description of T-Cell and Monocyte Populations in the Circulation of People with HIV Prior to AIDS-NHL Diagnosis

  2025cites this paper
• Senescence-associated IL-33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion

  2025cites this paper
• Application of Nano-Delivery Technology in Tumor Immunotherapy

  2025cites this paper
• Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma

  2025cites this paper
• Safety and efficacy of radiotherapy combined with immunotherapy in limited-stage small cell lung cancer a single-arm meta-analysis and systematic review

  2025cites this paper
• Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment

  2025cites this paper
• UiO-66 MOFs-Based "Epi-Nano-Sonosensitizer" for Ultrasound-Driven Cascade Immunotherapy against B-Cell Lymphoma.

  2025cites this paper
• A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle

  2024cites this paper
• Prognostic biomarker HIF1α and its correlation with immune infiltration in gliomas

  2024cites this paper
• FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics

  2024cites this paper
• Pyroptosis‐Inducing Biomaterials Pave the Way for Transformative Antitumor Immunotherapy

  2024cites this paper
• Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors

  2024cites this paper
• Peptide-directed interference of PD-1/PD-L1 binding increases B lymphocyte function after infectious bursal disease viral infection

  2024cites this paper
• Correlation between PD-1/PD-L1 and RANKL/OPG in chronic apical periodontitis model of Sprague-Dawley rats

  2024cites this paper
• Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme

  2024cites this paper
• TREM1 promotes cancer associated malignant phenotype through activated MAPK signaling pathway and predicts poor prognosis in gastric cancer

  2024cites this paper
• Radiation-Activated Resiquimod Prodrug Nanomaterials for Enhancing Immune Checkpoint Inhibitor Therapy.

  2024cites this paper
• Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosis

  2024cites this paper
• Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches

  2024cites this paper
• Comprehensive Analysis and Verification of the Prognostic Significance of Cuproptosis-Related Genes in Colon Adenocarcinoma

  2024cites this paper
• Engineering the Mechanical Stability of a Therapeutic Complex between Affibody and Programmed Death-Ligand 1 by Anchor Point Selection.

  2024cites this paper
• On-demand reprogramming of immunosuppressive microenvironment in tumor tissue via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immunotherapy using engineered gold nanoparticles for malignant tumor treatment.

  2024cites this paper
• Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

  2024cites this paper
• Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models

  2024cites this paper
• Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice.

  2024cites this paper
• Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions

  2024cites this paper
• Effect and Influencing Factors of Programmed Cell Death Protein-1 Inhibitor on Hepatitis B Virus Related Hepatocellular Carcinoma Undergoing Hepatic Arterial Chemotherapy

  2024cites this paper
• pH/glutathione-responsive theranostic nanoprobes for chemoimmunotherapy and magnetic resonance imaging of ovarian cancer cells.

  2024cites this paper
• Advances in and Prospects of Immunotherapy for Prostate Cancer.

  2024cites this paper
• Application of Traditional Chinese Medicine in Inhibiting the PD-1/PD-L1 Pathway in the Treatment of Gastric and Colon Cancers

  2024cites this paper
• Advances in breast cancer research using CRISPR/Cas9 system

  2024cites this paper
• Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults.

  2024cites this paper
• Cancer Cell-selective PD-L1 Inhibition via a DNA Safety Catch to Enhance Immunotherapy Specificity.

  2024cites this paper
• Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets

  2024cites this paper
• The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified

  2024cites this paper
• The advancement of siRNA-based nanomedicine for tumor therapy.

  2024cites this paper
• Clinical Observation of PD-1/PD-L1 Inhibitors Combined with Anti Angiogenic Drugs in the Treatment of Advanced/Unresectable Chronic Hepatitis B Related Hepatocellular Carcinoma Patients

  2024cites this paper
• Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures

  2024cites this paper
• Generation of B7‐H3 isoform regulated by ANXA2/NSUN2/YBX1 axis in human glioma

  2024cites this paper
• High expression of CCNB2 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in breast carcinoma

  2024cites this paper
• The New Era of Lung Cancer Therapy: Combining Immunotherapy with Ferroptosis.

  2024cites this paper
• Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation

  2024cites this paper
• Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma

  2024cites this paper
• PEGylated graphene oxide-mediated stimulation of vascular endothelial cells and responsive release of PD-1/PD-L1 inhibitor for efficient chemo-immunotherapy against cancer

  2024cites this paper
• Decitabine-based nanoparticles for enhanced immunotherapy of hepatocellular carcinoma via DNA hypermethylation reversal

  2024cites this paper
• Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

  2024cites this paper
• Engineering the Mechanical Stability of a Therapeutic Affibody/PD-L1 Complex by Anchor Point Selection

  2024cites this paper
• Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

  2024cites this paper
• Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity

  2023cites this paper
• Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

  2023cites this paper
• Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma

  2023cites this paper
• Development and experimental validation of a machine learning-based disulfidptosis-related ferroptosis score for hepatocellular carcinoma

  2023cites this paper
• Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics

  2023cites this paper
• A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy

  2023cites this paper
• Machine Learning-derived Multi-omics Prognostic Signature of Pyroptosis-related lncRNA with Regard to ZKSCAN2-DT and Tumor Immune Infiltration in Colorectal Cancer

  2023cites this paper
• Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening.

  2023cites this paper
• The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

  2023cites this paper
• Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors

  2023cites this paper
• Semiconducting Polymers for Cancer Immunotherapy

  2023cites this paper
• Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse.

  2023cites this paper
• Targeting EBV‐encoded products: Implications for drug development in EBV‐associated diseases

  2023cites this paper
• Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study

  2023cites this paper
• Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis

  2023cites this paper
• Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma

  2023cites this paper
• Identification of N7-methylguanosine-related lncRNAs for the risk stratification of hepatocellular carcinoma

  2023cites this paper
• High C1QTNF1 expression mediated by potential ncRNAs is associated with poor prognosis and tumor immunity in kidney renal clear cell carcinoma

  2023cites this paper
• When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.

  2023cites this paper
• Integrated analysis of SKA1-related ceRNA network and SKA1 immunoassays in HCC: A study based on bioinformatic

  2023cites this paper